Introduction
Methods
Trial Identification
Efficacy Measures
Costs
Statistical Methods
Compliance with Ethics Guidelines
Results
Trial name | Treatment |
N
| ASAS20 at Week 12 | ASAS40 at Week 12 | ||
---|---|---|---|---|---|---|
N
| % |
N
| % | |||
ATLAS [9] | Placebo | 107 | 22 | 20.6 | 14 | 13.1 |
Adalimumab 40 mg | 208 | 121 | 58.2 | 83 | 39.9 | |
M03-606 [30] | Placebo | 44 | 12 | 27.3 | 4 | 9.1 |
Adalimumab 40 mg | 38 | 18 | 47.4 | 17 | 44.7 | |
Huang [31] | Placebo | 115 | 35 | 30.4 | 11 | 9.6 |
Adalimumab 40 mg | 229 | 154 | 67.2 | 102 | 44.5 | |
RAPID-axSpA [10] | Placebo | 57 | 21 | 36.8 | 11 | 19.3 |
Certolizumab 200 mg | 65 | 37 | 56.9 | 26 | 40.0 | |
Certolizumab 400 mg | 56 | 36 | 64.3 | 28 | 50.0 | |
Calin [32] | Placebo | 39 | 9 | 23.1 | – | – |
Etanercept 25 mg | 45 | 27 | 60.0 | – | – | |
Gorman [33]a
| Placebo | 20 | 7 | 35.0 | – | – |
Etanercept 25 mg | 20 | 15 | 75.0 | – | – | |
Enbrel AS Study [11] | Placebo | 139 | 39 | 28.1 | – | – |
Etanercept 25 mg | 138 | 82 | 59.4 | – | – | |
Etanercept Study 314 [34] | Placebo | 51 | 19 | 37.3 | 11 | 21.6 |
Etanercept 25 mg | 150 | 107 | 71.3 | 80 | 53.3 | |
Etanercept 50 mg | 155 | 115 | 74.2 | 90 | 58.1 | |
Giardina [29] | Etanercept 50 mg | 25 | 15 | 60.0 | 11 | 43.0 |
Infliximab 5 mg/kg | 25 | 19 | 75.0 | 14 | 55.0 | |
Bao [12]b
| Placebo | 105 | 26 | 24.8 | 10 | 9.6 |
Golimumab 50 mg | 108 | 53 | 49.1 | 29 | 26.9 | |
GO-RAISE [35]c
| Placebo | 78 | 17 | 21.8 | 12 | 15.5 |
Golimumab 50 mg | 138 | 82 | 59.4 | 62 | 44.9 | |
ASSERT [13] | Placebo | 78 | 16 | 20.5 | 10 | 12.8 |
Infliximab 5 mg/kg | 201 | 124 | 61.9 | 99 | 49.3 | |
Braun [36] | Placebo | 35 | 10 | 27.2 | – | – |
Infliximab 5 mg/kg | 35 | 24 | 68.8 | – | – | |
MEASURE 1 [37]d
| Placebo | 122 | 35 | 28.7 | 16 | 13.1 |
Secukinumab 75 mg | 124 | 74 | 59.7 | 41 | 33.1 | |
Secukinumab 150 mg | 125 | 76 | 60.8 | 52 | 41.6 | |
MEASURE 2 [37]d
| Placebo | 74 | 21 | 28.4 | 8 | 10.8 |
Secukinumab 75 mg | 73 | 30 | 41.1 | 19 | 26.0 | |
Secukinumab 150 mg | 72 | 44 | 61.1 | 26 | 36.1 |
Network Meta-Analysis: ASAS20
Treatment | Response (95% CrI) | OR (95% CrI) | NNT (95% CrI) | Cost per responder (95% CrI) |
---|---|---|---|---|
Placebo | 27.9% (25.3%, 30.6%) | – | – | – |
Adalimumab | 63.6% (53.2%, 72.5%) | 4.5 (3.0, 6.7) | 2.8 (2.3, 3.9) | $26,888 ($21,720, $37,320) |
Certolizumab pegola
| 50.5% (32.9%, 68.4%) | 2.6 (1.3, 5.5) | 4.4 (2.5, 17.0) | $60,326 ($33,593, $232,542) |
Etanerceptb
| 62.0% (52.3%, 71.1%) | 4.2 (2.9, 6.2) | 2.9 (2.3, 4.0) | $28,199 ($22,483, $38,633) |
Golimumab | 60.2% (47.4%, 71.8%) | 3.9 (2.4, 6.5) | 3.1 (2.3, 5.0) | $30,417 ($22,550, $49,510) |
Infliximabc
| 71.7% (59.5%, 82.0%) | 6.6 (3.9, 11.6) | 2.3 (1.9, 3.1) | $28,175 ($22,903, $38,694) |
Secukinumab (without loading)d
| 60.3% (48.1%, 71.8%) | 4.0 (2.3, 6.6) | 3.1 (2.3, 5.1) | $33,847 ($25,149, $53,293) |
Secukinumab (with loading)d
| 60.3% (48.1%, 71.8%) | 4.0 (2.3, 6.6) | 3.1 (2.3, 5.1) | $67,694 ($50,299, $106,586) |
Network Meta-Analysis: ASAS40
Treatment | Response (95% CrI) | OR(95% CrI) | NNT(95% CrI) | Cost per responder(95% CrI) |
---|---|---|---|---|
Placebo | 13.5% (11.4%, 15.9%) | – | – | – |
Adalimumab | 49.2% (36.0%, 63.4%) | 6.2 (3.8, 10.8) | 2.8 (2.0, 4.3) | $26,898 ($19,483, $41,699) |
Certolizumab pegola
| 34.8% (18.8%, 56.2%) | 3.4 (1.5, 8.1) | 4.7 (2.3, 16.6) | $64,051 ($31,815, $227,020) |
Etanerceptb
| 41.4% (25.6%, 60.1%) | 4.6 (2.3, 9.3) | 3.6 (2.2, 8.0) | $34,406 ($20,866, $76,436) |
Golimumab | 38.6% (24.5%, 55.5%) | 4.0 (2.2, 7.8) | 4.0 (2.4, 8.5) | $39,030 ($23,760, $83,570) |
Infliximabc
| 51.5% (33.4%, 70.0%) | 6.8 (3.3, 14.8) | 2.6 (1.8, 4.9) | $32,508 ($21,954, $60,308) |
Secukinumab (without loading)d
| 42.4% (28.1%, 59.2%) | 4.7 (2.6, 9.1) | 3.5 (2.2, 6.6) | $37,850 ($24,274, $72,096) |
Secukinumab (with loading)d
| 42.4% (28.1%, 59.2%) | 4.7 (2.6, 9.1) | 3.5 (2.2, 6.6) | $75,701 ($48,547, $144,191) |